Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 10 | 2014 | 78 | 1.100 |
Why?
|
| Ovary | 4 | 2013 | 22 | 0.520 |
Why?
|
| Chickens | 7 | 2013 | 32 | 0.420 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 4 | 0.410 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 4 | 0.410 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 50 | 0.400 |
Why?
|
| Disease Models, Animal | 7 | 2013 | 517 | 0.400 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 94 | 0.390 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 111 | 0.380 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 192 | 0.220 |
Why?
|
| Animals | 8 | 2014 | 3255 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 350 | 0.150 |
Why?
|
| Azo Compounds | 1 | 2018 | 3 | 0.140 |
Why?
|
| Nitric Oxide Donors | 1 | 2018 | 7 | 0.140 |
Why?
|
| Amines | 1 | 2018 | 8 | 0.140 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 11 | 0.140 |
Why?
|
| Antifungal Agents | 1 | 2018 | 36 | 0.140 |
Why?
|
| Paclitaxel | 1 | 2014 | 49 | 0.110 |
Why?
|
| Metformin | 1 | 2014 | 15 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 17 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 42 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2013 | 12 | 0.100 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 16 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2013 | 53 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 39 | 0.100 |
Why?
|
| Female | 10 | 2014 | 12904 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 323 | 0.100 |
Why?
|
| Fluorocarbons | 1 | 2011 | 11 | 0.090 |
Why?
|
| Albumins | 1 | 2011 | 18 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2018 | 156 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2011 | 42 | 0.080 |
Why?
|
| Antigens, Neoplasm | 2 | 2009 | 41 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2014 | 188 | 0.080 |
Why?
|
| Autoantibodies | 2 | 2009 | 62 | 0.080 |
Why?
|
| Ultrasonography, Doppler | 1 | 2010 | 11 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 34 | 0.080 |
Why?
|
| Humans | 10 | 2018 | 22823 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2011 | 203 | 0.080 |
Why?
|
| Algorithms | 1 | 2011 | 295 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 227 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2014 | 122 | 0.040 |
Why?
|
| Disease Progression | 2 | 2013 | 521 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 439 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 591 | 0.040 |
Why?
|
| Ovarian Follicle | 2 | 2009 | 11 | 0.040 |
Why?
|
| Fusarium | 1 | 2018 | 1 | 0.040 |
Why?
|
| Immunoassay | 2 | 2009 | 32 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2018 | 72 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 38 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 22 | 0.030 |
Why?
|
| Lovastatin | 1 | 2014 | 7 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 21 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 129 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 161 | 0.030 |
Why?
|
| Poultry Diseases | 1 | 2013 | 2 | 0.030 |
Why?
|
| Apoptosis | 1 | 2014 | 180 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 9 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 59 | 0.020 |
Why?
|
| Mice | 1 | 2014 | 1228 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1412 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 7 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 15 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 15 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 25 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 22 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2007 | 2 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2007 | 4 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2007 | 6 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 17 | 0.020 |
Why?
|
| Ovarian Cysts | 1 | 2007 | 4 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2007 | 12 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2007 | 50 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2007 | 210 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2976 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 3717 | 0.010 |
Why?
|
| Adult | 1 | 2007 | 6896 | 0.010 |
Why?
|
| Aged | 1 | 2007 | 7412 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 7873 | 0.010 |
Why?
|